Inhaled corticosteroids were introduced for the treatment of asthma around 15 years ago. Topically active steroids were used initially to replace oral steroids in patients with severe chronic asthma. The inhaled route is considered to be much safer than the oral route for steroid treatment'2 and over the last few years physicians have recommended the earlier introduction of inhaled steroids to patients with less severe or moderate asthma." There is growing evidence that inhaled corticosteroids decrease airway hyperreactivity, and to a greater extent than beta2 agonists. 9 The safety margin with topical application is high owing to low systemic concentrations of the drug. The safety margin also increases when the elimination rate from the body is high, as with budesonide."' Our study was undertaken to investigate the effects of low doses of inhaled corticosteroids in outpatients with mild symptomatic asthma treated with inhaled beta2 agonists only.
Methods

PATIENTS
The inclusion criteria were a beta2 agonist consumption of at least 35 puffs during the run in week and a mean variation of 10-30% in peak expiratory flow (PEF) over the last four days of the run in week with a mean PEF of at least 75 % ofpredicted normal values." The patients had to be compliant and to have filled in their diary cards correctly during the run in week. Patients were excluded if they were receiving inhaled or oral corticosteroids or using spacers for beta2 agonist administration. We also excluded patients with important concomitant diseases likely to interfere with the accomplishment of the study and those who had had a respiratory infection or an acute asthma exacerbation during the month before the start of the study.
The patients gave their informed consent. Approval for the study, which was conducted according to the Declaration of Helsinki (1975) , was obtained from the regional ethics committee.
STUDY DESIGN
The study had a multicentre, randomised, double blind, parallel group, placebo controlled design, consisting of six treatment weeks (placebo, or twice daily-budesonide 100 or 200 jug). It started with one run in week if the patient's medication was an inhaled beta2 agonist only. If the medication also included oral bronchodilators, these were replaced by an inhaled beta2 agonist during a washout week before the run in week. To increase peripheral lung and decrease oropharyngeal deposition of budesonide, the patients were instructed to use a 750 ml spacer (Nebuhaler) connected to a metered dose inhaler for inhalation of the study drug. The beta2 agonist on a regular or "as required" basis (or both) was administered by a metered dose inhaler without a spacer. Patients were also instructed about the sequence ofpeak flow measurement and drug administration (namely, PEF measurement followed by inhalation of beta2 agonist (ifneeded) and then by inhalation of budesonide). The patients were treated by general practitioners at health care centres and chest physicians at lung clinic outpatient departments. (10) 14 (7) 13 ( the morning peak flow measurement until bedtime (day registration) and from bedtime until the following morning peak flow measurement -(night registration). Subjects also recorded an asthma symptoms score according to a four grade scale (0=no symptoms, 1 = mild symptoms, 2= moderate symptoms, 3 = severe symptoms). Adverse experiences were recorded daily. Diary cards were mailed to the doctor after two and four weeks, and brought to the clinic at the last visit after six weeks of treatment. The patients made three visits to the clinic during the trial. At visit 1 patients were informed of the purpose of the study and instructed in the use of the peak flow meter and how to score asthma symptoms and report adverse experiences. At visit 2 one week later (two weeks later if oral bronchodilators had to be replaced by inhaled beta2 agonist) the diary cards were checked carefully, and if the inclusion criteria were fulfilled the patient was randomly allocated to one of the three treatment groups. They were then equipped with a budesonide canister (of identical appearance for placebo and active drug), a spacer, and three diary cards (for three fortnights) and informed about inhalation technique. Patients were also carefully instructed on how their beta2 agonist should be taken in case of need-that is, by slowly decreasing the number of puffs during phases of improvement and increasing them rapidly during deterioration. At visit 3 the patients were asked to assess the six weeks of treatment in relation to the run in week according to whether their asthma was much improved, improved, unchanged, worse, or much worse.
ANALYSIS
The main variables analysed were PEF and beta2 agonist consumption. The effectiveness of treatment was assessed by both within group and between group analysis with appropriate parametric (t test) and non-parametric (van Elteren test, a stratified Wilcoxon test) statistics. The level of significance was set at 5%.
Results
One hundred and four patients with mild symptomatic asthma entered the study. ,ug budesonide by comparison with placebo  (table 2) .
The night time asthma symptoms score decreased from 08 to 04 after both doses of budesonide (p < OO1) by comparison with placebo. Day time recordings fell significantly in relation to placebo only after 400 jg budesonide (table 2) .
Assessment of asthma after six weeks of treatment showed that 66% of patients taking budesonide were improved (30% much improved and 36% improved). In the placebo group 30% improved. The placebo effect was significantly less than the effect of active treatment (p < 0 01). We found no significant differences between the active treatments.
There was no report of adverse experiences among the budesonide treated patients that could be connected with the drug or additives. In the placebo group two patients reported a sore throat.
Discussion
There is increasing evidence that epithelial damage, along with extravasation of plasma, bronchial oedema, and cell infiltration, may be present even in mild asthma. ' 
